Contango ORE, Inc. (“Contango” or the “Company”) (NYSE American: CTGO) announced today that it filed with the Securities and Exchange Commission its Form 10-Q for the quarter ended June 30, 2025 (“Q2-2025”) compared with the quarter ended June 30, 2024 (“Q2-2024”). https://mma.prnewswire.com/media/2749979/Contango_Ore_Contango_Announces_Record_High__23_0_Million_in_Inc.jpg Rick Van Nieuwenhuyse, President and CEO of the Company, stated, “Production during the […]

MSA Safety Incorporated (NYSE: MSA), a global leader in the development of advanced safety products and solutions that protect people and facility infrastructures, today announced that Julie A. Beck has been named Senior Vice President, Chief Financial Officer and Treasurer, effective August 18, 2025. Ms. Beck previously served as Senior Vice President and Chief Financial

First Half Revenue of $45,118 Prepaid subscription fees received from customers for our SaaS service were $1.5 Million. FiEE, Inc.(NASDAQ:FIEE) (“FiEE” or the “Company”), a technology company integrating IoT, connectivity and AI to redefine brand management solutions in the digital era, today announced its unaudited financial results for the three and six months ended June

MDU Resources Group, Inc. (NYSE: MDU) today announced the election of Charles M. Kelley and Tammy J. Miller to its board of directors, effective Aug. 12, 2025. https://mma.prnewswire.com/media/435402/MDUR_logo_Logo.jpg Kelley brings more than four decades of experience in the natural gas industry, including a distinguished 25-year career at ONEOK, Inc., where he most recently served as

Planet 13 Announces Q2 2025 Financial Results GlobeNewswire August 13, 2025 Q2 2025 Revenue of $26.9 million Q2 2025 Net loss of $13.3 million Q2 2025 Adjusted EBITDA loss of $2.4 million All figures are reported in United States dollars ($) unless otherwise indicated LAS VEGAS, Aug. 13, 2025 (GLOBE NEWSWIRE) — Planet 13 Holdings

(NASDAQ:IRD), – Positive 12-month Phase 1/2 clinical data in adult cohort and early pediatric clinical data support potential for meaningful vision restoration with OPGx-LCA5 – – FDA grants Regenerative Medicine Advanced Therapy (RMAT) designation for OPGx-LCA5 – – Positive topline results reported from VEGA-3 and LYNX-2 Phase 3 trials with Phentolamine Ophthalmic Solution 0.75% –

(TSX:APS),(Pinksheets:APTOF),(PinkSheets:APTOF), Tuspetinib Continues to Demonstrate Excellent Safety and Complete Responses in the TUSCANY Clinical Trial of Tuspetinib in AML Triple Drug Frontline Therapy at 120 mg Dose Cohort Safety Review Committee (CSRC) Recommends Tuspetinib Dose Escalation to 160 mg Dose Hanmi Continues to Support Development of Tuspetinib SAN DIEGO and TORONTO, Aug. 13, 2025 (GLOBE

LOUISVILLE, Ky., Aug. 13, 2025 (GLOBE NEWSWIRE) — Onco360(R), the nation's leading independent Specialty Pharmacy, has been selected as a pharmacy partner by Jazz Pharmaceuticals for Modeyso(TM) (dordaviprone). It is indicated for the treatment of adult and pediatric patients one year of age and older with diffuse midline glioma harboring an H3 K27M-mutation with progressive

(NasdaqGM:SCYX), First new patient dosed in Phase 3 MARIO study following the lifting of the FDA clinical hold, triggering a $10M milestone payment from GSK. An additional $20M milestone will be triggered upon the six month anniversary of the new patient dosing; as previously disclosed GSK disputes these milestone payments. SCYNEXIS vigorously disagrees with GSK's

Opus Genetics Announces Financial Results for Second Quarter 2025 and Provides Corporate Update GlobeNewswire August 13, 2025 – Positive 12-month Phase 1/2 clinical data in adult cohort and early pediatric clinical data support potential for meaningful vision restoration with OPGx-LCA5 – – FDA grants Regenerative Medicine Advanced Therapy (RMAT) designation for OPGx-LCA5 – – Positive